Adverse neurobiological effects of long-term use of neuroleptics: Human and animal studies

Journal of Psychiatric Research

Volumn 32, Issue 3-4, 1998, Pages 201-214

  Jeste, Dilip V ^a   Lohr, James B ^a   Eastham, John H ^a   Rockwell, Enid ^a   Caligiuri, Michael P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; COGNITIVE DEFECT; DRUG WITHDRAWAL; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PERFORMANCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0032071171     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(97)00018-6     Document Type: Article

References (85)

1. Avorn, J., Bohn, R. L., Mogun, H., Gurwitz, J. H., Monane, M., Everitt, D., & Walker, A. (1995). Neuroleptic drug exposure and treatment of Parkinsonism in the elderly: A case-control study. American Journal of Medicine, 99(1), 48-53.
2. Benes, F. M., Paskevich, P. A., & Domesick, V. (1983). Haloperidol-induced plasticity of axon terminals in rat substantia nigra. Science, 221, 969-971.
3. Berman, I., Merson, A., Allan, E., Alexis, C., Sison, C. & Losonczy, M. (1995). Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison with haloperidol. NCDEU 35th Annual Meeting, poster No. 93.
4. Berman, I., Merson, A., Rachov-Pavlov, J., Allan, E., Davidson, M., & Losonczy, M. F. (1996). Risperidone in elderly schizophrenic patients: An open-label trial. American Journal of Geriatric Psychiatry, 4(2), 173-179.
5. Bilder, R. M., Turkel, E., Lipschutz-Broch, L., & Lieberman, J. A. (1992). Antipsychotic medication effects on neuropsychological functions. Psychopharmacology Bulletin, 28, 353-366.
6. Borison, R. L., Davidson, M. & Berman, I. (1994). Risperidone treatment in elderly patients with schizophrenia or dementia (Poster). APA 46th Institute of Hospital and Community Psychiatry.
7. Bottcher, J. (1975). Morphology of the basal ganglia in Parkinson's disease. Acta Neurologica Scandinavica Supplementum, 62, 1-87.
8. Brizzee, K. R., Samorajski, T., Smith, R. C. & Brizzee, D. L. (1981). The effect of age and chronic neuroleptic drug treatment on cell populations in the neostriatum of Fischer 344 rats. In Enna, S.J., Samorajski, T. & Beer, B.(Eds), Brain neurotransmitters and receptors in aging and age-related disorders (pp. 59-80). New York: Raven Press.
9. Buchanan, R. W., Holstein, C., & Breier, A. (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry, 36, 717-725.
10. Bugiani, O., Salvariani, S., Perdelli, F., Mancardi, G. L., & Leonardi, A. (1978). Nerve cell loss with aging in the putamen. European Neurology, 17, 286-291.
11. Casey, D. E. & Hansen, T. E. (1984). Spontaneous dyskinesias. In Jeste, D. V. & Wyatt, R. J. (Eds), Neuropsychiatric movement disorders (pp. 67-95). Washington, D.C.: American Psychiatric Press.
12. Cassens, G., Inglis, A. K., Appelbaum, P. S., & Gutheil, T. G. (1990). Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bulletin, 16(3), 477-499.
13. Cazullo, C. L., Goldwurm, G. F. & Vanni, F. (1965). Correlations between chemical structures of psychotropic drugs and histological features experimentally induced in the central nervous system. In Bischoff, L. F. (Ed.), Proceedings of the Fifth International Congress of Neuropathology (pp. 842-853). Amsterdam: Excerpta Medica.
14. Chakos, M. H., Lieberman, J. A., Alvir, J., Bilder, R., & Ashtari, M. (1995). Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine (letter). Lancet, 345(8947), 456-457.
15. Chakos, M. H., Lieberman, J. A., Bilder, R. M., Borenstein, M., Lerner, G., Bogerts, B., Wu, H., Kinon, B., & Ashtari, M. (1994). Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry, 151(10), 1430-1436.
16. Classen, W., & Laux (1988). Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatry, 21(6), 295-297.
17. Cohen, G., & Spina, M. B. (1989). Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Annals of Neurology, 26, 689-690.
18. Dom, R. (1967). Local glial reaction in the CNS of albino-rats in response to the administration of a neuroleptic drug (butyrophenone). Acta Neurol Psychiatrica Belg, 67, 755-762.
19. Egan, M. F., Hurd, Y., Hyde, T. M., Weinberger, D. R., Wyatt, R. J., & Kleinman, J. E. (1994). Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse, 18, 178-189.
20. Eitan, N., Levin, Y., Ben-Artzi, E., Levy, A., & Neumann, M. (1992). Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatrica Scandinavica, 85, 74-76.
21. Gariano, R. F., Young, S. J., Jeste, D. V., Segal, D. S., & Groves, P. M. (1991). Effects of long-term administration of haloperidol on electrophysiological properties of rat mesencephalic neurons. Journal of Pharmacology and Experimental Therapeutics, 225, 108-113.
22. Gerlach, J. (1975). Long-term effect of perphenazine on the substantia nigra in rats. Psychopharmacologia, 45, 51-54.
23. Gladsjo, J. A., Eastham, J. H. & Jeste, D. V. (1998). Cognitive impairment in older schizophrenia patients: Etiology, assessment, and management. In Bermanzohn, P. & Hwang, M. Y. (Eds), Management of schizophrenia with comorbid conditions, in press.
24. Goetz, C. G. (1983). Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology, 40, 325-326.
25. Goldberg, T. E., Greenberg, R. D., Griffin, S. J., Gold, J. M., Kleinman, J. E., Pickar, D., Schulz, S. C., & Weinberger, D. R. (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry, 162, 43-48.
26. Gross, H. & Kaltenbach, E. (1969). Neuropathological findings in persistent hyperkinesia after neuroleptic long-term therapy. In Cerletti, A. & Bove, F. J. (Eds) The present status of psychotropic drugs. Amsterdam: Excerpta Medica.
27. Hackenberg, P., & Lange, E. (1975). Tierexperimenteller Beitrag zum problem der irreversiblen hirnschadigung bei der neuroleptica-langzeittherapie. Experimentell Pathologie, 10(3-4), 132-142.
28. Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34, 702-712.
29. Han, Z., Kyatt, B. L., Kochman, K. A., DeSouza, E. B., & Roth, G. S. (1989). Effect of aging on concentrations of D2-receptor-containing neurons in the rat striatum. Brain Research, 498(2), 299-307.
30. Hardie, R. J., & Lees, A. J. (1988). Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of Neurology, Neurosurgery and Psychiatry, 51, 850-854.
31. Heaton, R. K. & Drexler, M. (1987). Clinical neuropsychological findings in schizophrenia and aging. In Miller, N. E. & Cohen, G. D. (Eds), Schizophrenia and aging (pp. 145-161). New York: The Guilford Press.
32. Heaton, R., Paulsen, J., McAdams, L. A., Kuck, J., Zisook, S., Braff, D., Harris, M. J., & Jeste, D. V. (1994). Neuropsychological deficits in schizophrenia: Relationship to age, chronicity and dementia. Archives of General Psychiatry, 51, 469-476.
33. Heimer, L., Alheid, G. F. & Zaborsky, L. (1977). Basal ganglia. In Paxinos, G. (Ed.), The rat nervous system. Sydney: Academic Press.
34. Jellinger, K. (1977). Neuropathological findings after neuroleptic long-term therapy. In Roizen, L., Shiraki, H. & Grcevic, N. (Eds), Neurotoxicology (pp. 25-42). New York: Raven Press.
35. Jesberger, J. A., & Richardson, J. S. (1991). Oxygen free radicals and brain dysfunction. International Journal of Neuroscience, 57(1-2), 1-17.
36. Jeste, D. V. (Ed.) (1986). Neuropsychiatric dementias: current perspectives. Washington, D.C.: American Psychiatric Press.
37. Jeste, D. V., & Caligiuri, M. P. (1993). Tardive dyskinesia. Schizophrenia Bulletin, 19(2), 303-315.
38. Jeste, D. V., Caligiuri, M. P., Paulsen, J. S., Heaton, R. K., Lacro, J. P., Harris, M. J., Bailey, A., Fell, R. L., & McAdams, L. A. (1995). Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 patients. Archives of General Psychiatry, 52, 756-765.
39. Jeste, D. V., Eastham, J. H., Lacro, J. P., Gierz, M., Field, M. G., & Harris, M. J. (1996). Management of late-life psychosis. Journal of Clinical Psychiatry, 57(3), 39-45.
40. Jeste, D. V., Lohr, J. B., & Manley, M. (1992). Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology, 106, 154-160.
41. Jeste, D. V., Wisniewski, A. & Wyatt, R. J. (1986). Neuroleptic-associated "Tardive" syndromes. In Roy, A. (Ed.), Schizophrenia: the psychiatric clinics of North America. Vol. 9:1 (pp. 183-192). New York: Plenum Press.
42. Jeste, D. V. & Wyatt, R. J. (1982). Understanding and treating tardive dyskinesia. New York: Guilford Press, Inc.
43. Kane, J. M., Jeste, D. V., Barnes, T. R. E., Casey, D. E., Cole, J. O., Davis, J. M., Gualtieri, C. T., Schooler, N. R., Sprague, R. L. & Wettstein, R. M. (1992). Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association.
44. Kane, J. M., Woerner, M., & Lieberman, J. (1988). Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology, 8(4), 52S-56S.
45. Kane, J. M., Woerner, M. G., Pollack, S., Safferman, A. Z., & Lieberman, J. A. (1993). Does clozapine cause tardive dyskinesia? Journal of Clinical Psychiatry, 54, 327-330.
46. Keshavan, M. S., Bagwell, W. W., Haas, G. L., Sweeney, J. A., Schooler, N. R., & Pettegrew, J. W. (1994). Changes in caudate volume with neuroleptic treatment. Lancet, 344, 1434.
47. Lohr, J. B. (1991). Oxygen radicals and neuropsychiatric illness: Some speculations. Archives of General Psychiatry, 48, 1097-1106.
48. Lohr, J.B., Browning, J. & Jeste, D. V. (1991). Neuroleptic-induced striatal neuron loss: relationship to age. Society for Neuroscience Abstracts,
49. Lohr, J., Wisniewski, A. & Jeste, D. V. (1986). Neurological aspects of tardive dyskinesia. In Nasrallah, H. A. & Weinberger, D. R. (Eds), The neurology of schizophrenia (pp. 97-119). Amsterdam: Elsevier Science Publishers.
50. Mackiewicz, J., & Gershon, S. (1964). An experimental study of the neuropathological and toxicological effects of chlorpromazine and reserpine. Journal of Neuropsychiatry, 5, 159-169.
51. Mahadik, S. P., Laev, H., Korenovsky, A., & Karpiak, S. E. (1988). Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biological Psychiatry, 24, 199-217.
52. Manschreck, T. C., Redmond, D. A., & Beaudette, S. M. (1994). Clozapine in the back wards. Annals of Clinical Psychiatry, 6(4), 215-225.
53. Marsden, C. D., & Jenner, P. (1980). The pathophysiology of extra-pyramidal side-effects of neuroleptic drugs. Psychological Medicine, 10, 55-72.
54. McNeill, T. H., & Koek, L. L. (1990). Differential effects of advancing age on neurotransmitter cell loss in the substantia nigra and striatum of C57BL/6N mice. Brain Research, 531(1-2), 107-117.
55. Meshul, C. K., & Casey, D. E. (1989). Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Research, 489, 338-346.
56. Miller, R., Chouinard, G. (1993). Loss of striatal cholinergic neurons as a basis for tardive and 1-dopa-induced dyskinesias, neuroleptic-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry, 34(10), 713-738.
57. Murphy, G. M., Lim, K. O., Wieneke, M., Ellis, W. G., Forno, L. S., Hoff, A. L. & Nordahl, T. (1997). No increase in the frequency of Alzheimer's disease in elderly schizophrenics: a neuropathologic study. AAGP 10th Annual Meeting and Symposium, Orlando Fl., p. 2.
58. Nielsen, E. B., & Lyon, M. (1978). Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (fluphenthixol) in rats. Psychopharmacology, 59, 85-89.
59. Pakkenberg, H., Fog, R., & Nilakantan, B. (1973). The long-term effect of perphenazine enanthate on the rat brain: Some metabolic and anatomical observations. Psychopharmacologia, 29, 329-336.
60. Pandurangi, A. K., Devi, V., Channabasavanna, S. M. (1980). Caudate atrophy in irreversible tardive dyskinesia (a pneumoencephalographic study). Journal of Clinical Psychiatry, 41, 229-231.
61. Pasik, P., Pasik, T. & DiFiglia, M. (1979). The internal organization of the neostriatum in mammals. In Divac, I. & Oberg, R. G. E. (Eds), The neostriatum (pp. 5-36). New York: Pergamon Press.
62. Paulsen, J. S., Heaton, R. K., Sadek, J. R., Perry, W., Delis, D. C., Braff, D., Kuck, J., Zisook, S., & Jeste, D. V. (1995). The nature of learning and memory impairments in schizophrenia. Journal of the International Neuropsychological Society, 1, 88-99.
63. Paxinos, E. & Watson, C. (1986). Rat brain in sterotoxic coordinates (2nd edn). Orlando, Florida: Academic Press.
64. Rajput, A. H., Rozdilsky, B., Hornykiewicz, O., Shannak, K., & Lee, T., Seeman, P. (1982). Reversible drug-induced parkinsonism: Clinicopathologic study of two cases. Archives of Neurology, 39(10), 644-646.
65. Roizin, L., True, C., & Knight, M. (1959). Structural effects of tranquilizers. Research Publications-Association for Research in Nervous and Mental Disease, 37, 285-324.
66. Sachdev, P. (1995). The epidemiology of drug-induced akathisia: Part II Chronic, tardive, and withdrawal akathisias. Schizophrenia Bulletin, 21(3), 451-461.
67. Sakalis, G., Curry, S. H., Mould, G. P., & Lader, M. H. (1972). Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clinical Pharmacology and Therapeutics, 13(6), 931-946.
68. Saltz, B. L., Woerner, M. G., Kane, J. M., Lieberman, J. A., Alvir, J. M., Bergmann, K. J., Blank, K., Koblenzer, J., & Kahaner, K. (1991). Prospective study of tardive dyskinesia incidence in the elderly. Journal of the American Medical Association, 266, 2402-2406.
69. Scatton, B., Garrett, C., & Julow, L. (1975). Acute and subacute effects of neuroleptics on dopamine synthesis and release in the rat striatum. Archives of Pharmacology, 289, 419-434.
70. Schooler, N., & Kane, J. M. (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry, 39, 486-487.
71. See, R. E., Chapman, M. A., & Meshul, C. K. (1992). Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. Synapse, 12, 147-154.
72. Smith, J. M., Baldessarini, R. J. (1980). Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Archives of General Psychiatry, 37, 1368-1373.
73. Sommer, H. & Quandt, J. (1974). Langzeibehandlung mit chlorpromazine im tierexperiment. In Proceedings of the Sixth International Congress of Neuropathology (pp. 466-491). Paris: Masson and Cie.
74. Spohn, H. E., & Strauss, M. E. (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology, 98, 367-380.
75. Stephen, P. J., & Williamson, J. (1984). Drug induced parkinsonism in the elderly. Lancet, 2(8411), 1082-1083.
76. Tamminga, C. A., Dale, J. M., Goodman, L., Kaneda, H., & Kaneda, N. (1990). Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology, 102, 474-478.
77. Tarsey, D. (1989). Neuroleptic-induced movement disorders. In Quinn, N. P. & Jenner, P. G. (Eds), Disorders of movement, clinical, pharmacological and physiological aspects (pp. 361-393). London: Academic Press.
78. Terry, R. D., & DeTeresa, R. (1982). The importance of video editing in automated image analysis in studies of the cerebral cortex. Journal of the Neurological Sciences, 53(3), 413-421.
79. Terry, R. D., Peck, A., DeTeresa, R., Schechter, R., & Horoupian, D. S. (1981). Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Annals of Neurology, 10, 184-192.
80. Uranova, N. A., Orlovskaya, D. D., Apel, K., Klintsova, A. J., Haselhorst, U., & Schenk, H. (1991). Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse, 7, 253-259.
81. Waddington, J. L., Cross, A. J., Gamble, S. J., & Bourne, R. C. (1983). Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science, 220, 530-532.
82. Wilson, J. A., Primrose, W. R., & Smith, R. G. (1987). Prognosis of drug-induced Parkinson's disease. Lancet, 1(8530), 443-444.
83. Wisniewski, H. M., Constantinidis, J., Wegiel, J., Bobinski, M., & Tarnawski, M. (1994). Neurofibrillary pathology in brains of elderly schizophrenics treated with neuroleptics. Alzheimer Disease and Associated Disorders, 8(4), 211-227.
84. Yassa, R., & Jeste, D. V. (1992). Gender differences in tardive dyskinesia: A critical review of the literature. Schizophrenia Bulletin, 18(4), 701-715.
85. Yassa, R., Nair, N. P. V., & Jeste, D. V. (1997). Neuroleptic-induced movement disorders (pp. 1-494). Cambridge, U.K.: Cambridge University Press.